{"id":8442,"date":"2025-08-24T10:02:37","date_gmt":"2025-08-24T07:02:37","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8442"},"modified":"2025-08-24T10:02:37","modified_gmt":"2025-08-24T07:02:37","slug":"management-of-hypertension-in-primary-care-key-points","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/management-of-hypertension-in-primary-care-key-points\/","title":{"rendered":"Management of Hypertension in Primary Care \u2013 Key Points"},"content":{"rendered":"
Management of Hypertension in Primary Care \u2013 Key Points<\/div>\n
<\/div>\n
Medscape : Douglas S. Paauw, August 15, 2025<\/div>\n
\u2013 University of Washington (Primary Care & Medical Education). Based on: 2025 AHA\/ACC Guideline for the Management of Hypertension in Adults (Circulation & JACC, Aug 14, 2025) and ESC Guidelines 2024 on Hypertension:<\/div>\n
<\/div>\n
1. Secondary Hypertension \u2013 Most Common Causes<\/span><\/div>\n
\u2022 Essential hypertension = 90\u201395% of cases.<\/span><\/div>\n
\u2022 More common secondary causes:<\/span><\/div>\n
* Obstructive sleep apnea: 25\u201350%<\/div>\n
* Hyperaldosteronism: 8%<\/div>\n
* Atherosclerotic renal artery stenosis: 5%<\/div>\n
* Drug\/alcohol abuse: 4%<\/div>\n
\u2022 Rare causes (e.g., pheochromocytoma, coarctation, Cushing\u2019s) = <0.1%.<\/span><\/div>\n
2. Initial Treatment of Newly Diagnosed Hypertension<\/span><\/div>\n
\u2022 If BP >20\/10 mmHg above target \u2192 start two-drug therapy.<\/span><\/div>\n
\u2022 Stage 1 hypertension (mild elevation) \u2192 usually starts with one drug.<\/span><\/div>\n
3. When One Drug Fails to Achieve the Target<\/span><\/div>\n
\u2022 Doubling the dose of a single drug lowers BP only slightly (e.g., valsartan 80 \u2192 160 mg = \u21933\/0.8 mmHg).<\/span><\/div>\n
\u2022 Adding a second drug (e.g., hydrochlorothiazide) gives a greater effect (\u219312\/6 mmHg).<\/span><\/div>\n
\u2022 Meta-analysis: combination therapy lowers BP ~5x more than dose doubling.<\/span><\/div>\n
4. Resistant Hypertension \u2013 Modern Approach<\/span><\/div>\n
\u2022 First step: assess adherence, as up to 80% of patients take fewer drugs than prescribed.<\/span><\/div>\n
\u2022 If true resistant hypertension (\u22653 drugs, documented adherence):<\/span><\/div>\n
* Spironolactone lowers SBP by 16 mmHg \/ DBP by 9 mmHg.<\/div>\n
* Amiloride shown to be equivalent to spironolactone (SBP reduction ~13.6 mmHg).<\/div>\n
\u2022 MRAs(Mineralocorticoid receptor antagonists) recommended by ACC\/AHA guidelines.<\/span><\/div>\n
5. Clinical Pearls<\/span><\/div>\n
\u2022 Always consider sleep apnea and hyperaldosteronism as leading secondary causes.<\/span><\/div>\n
\u2022 Two drugs are better than one in most patients.<\/span><\/div>\n
\u2022 Spironolactone (or amiloride) is the best add-on for resistant hypertension.<\/span><\/div>\n
<\/div>\n
https:\/\/www.acc.org\/Latest-in-Cardiology\/Journal-Scans\/2025\/08\/14\/15\/36\/New-ACC-AHA-Guideline-Addresses-Prevention-Detection-Evaluation-and-Management-of-HBP<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Management of Hypertension in Primary Care \u2013 Key Points Medscape : Douglas S. Paauw, August 15, 2025 \u2013 University of Washington (Primary Care & Medical Education). Based on: 2025 AHA\/ACC Guideline for the Management of Hypertension in Adults (Circulation & JACC, Aug 14, 2025) and ESC Guidelines 2024 on Hypertension: 1. Secondary Hypertension \u2013 Most […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8442","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8442"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8442\/revisions"}],"predecessor-version":[{"id":8443,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8442\/revisions\/8443"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}